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Abstract
There is an increasing body of evidence suggesting that metal homeostasis is dysregulated in the pathology of Alzheimer’s
disease (AD). Although expression levels of several transporters belonging the SLC30 family, which comprises
predominantly zinc transporters, have been studied in the AD brain, SLC30A10 (ZnT10) has not been studied in this
context. To determine if dysregulated expression of ZnT10, which may transport both Zn and Mn, could be a factor that
contributes to AD, we investigated if there were differences in ZnT10 mRNA levels in specimens of frontal cortex from AD
patients and controls and also if brain tissue from the APP/PS1 transgenic (Tg) mouse model showed abnormal levels of
ZnT10 mRNA expression. Our results show that ZnT10 is significantly (P,0.01) decreased in the frontal cortex in AD.
Furthermore, we observed a significant decrease in ZnT10 mRNA levels in the APP/PS1-Tg mice compared with wild-type
controls (P,0.01). Our results suggest that this dysregulation in ZnT10 could further contribute to disease progression.
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Introduction
Zn is thought to be involved in Alzheimer’s disease (AD)
development and progression, however there are many questions
that remain unanswered. It is evident that the transcription of
amyloid precursor protein (APP) is regulated by the Zn-dependent
transcription factors Sp1 and NF-kB [1]. In addition, Zn is able to
promote formation of amyloid-b (Ab) oligomers and aggregates at
physiological concentrations available in the brain by binding Ab
at 3 N-terminal histidine residues [2]. Moreover, the protease
responsible for APP cleavage, a-secretase, is inhibited by Zn [2]. It
follows that dysregulation of mechanisms that ordinarily act to
maintain Zn homeostasis within brain tissue may contribute to
AD. The possible involvement of selected Zn transporters in AD
has been investigated already, but more comprehensive study in
this area is warranted. Regulation of Zn is maintained through two
families of Zn transporters; ZnTs and ZIPs. Human studies of Zn
transporter dysregulation in AD have focussed on the ZnTs, with
regulation of ZnT1, 3, 4, 6 and 7 being studied previously. Up-
regulation of ZnT1 protein in the hippocampus in AD brain tissue
has been observed [3]. It is thought that this increase in ZnT1
expression in the disease state causes an increase in Zn ions
available in the extracellular space for initiation of Ab deposition
and senile plaque formation [4]. In the preclinical disease states -
mild cognitive impairment and pre-clinical AD- an initial decrease
in ZnT1 is also observed before progression to AD. Positive
correlation between Braak score (NFT pathology) and ZnT1 levels
has also been reported [2,4]. Additional members of the ZnT
family of Zn transporters, ZnT4 and ZnT6, have also been
implicated in AD progression, with elevated protein levels of both
transporters in the hippocampus of AD patients [5].
It has been suggested that ZnT6, located in the Golgi apparatus,
mediates accumulation of Zn therefore enabling Zn to promote
Ab formation by binding to APP and inhibiting a-secretase [4].
ZnT4 is found in the lysosomal and endosomal compartments in
hippocampal tissue, where an increase in expression observed in
AD patients [5] may drive the sequestration of Zn, consistent with
Ab accumulation in these vesicles in the post-mortem AD brain
[6].
ZnT3 localises predominantly to the membranes of Zn-rich
synaptic vesicles in the hippocampus [7], and Znt3 knockout mice
are devoid of Zn in these otherwise Zn-enriched terminals.
Furthermore, increased amyloid deposition in the brain of female
mice is co-incident with an age-dependent hyperactivity of the
Znt3 protein in the female Tg2576 mouse model compared with
the male mice, which is abolished in the Znt3 knockout mouse [8].
This result is particularly interesting in light of the higher
incidence of AD in women compared with men. In addition, in
the Tg2576 mouse model of AD the ablation of Znt3 inhibits the
development of Ab pathology. The levels of mRNA and protein
expression of ZnT3 appear to be lower however, in the cortical
regions of human AD patients [9,10], in contrast to the mouse
model where Znt3 protein levels are increased [11].
Manganese (Mn) is another trace element that is essential in the
body. It is an important co-factor for several enzymes in the brain,
including Mn-superoxide dismutase and glutathione synthetase. It
is also needed for adequate neurotransmitter synthesis and
metabolism [12]. As with Zn homeostasis, Mn levels in the body
are tightly controlled, with several manganese transporter systems
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being characterised. Intriguingly other Zn transporters (ZIP8 and
ZIP14) have been associated with Mn transport, although their
levels of expression in the brain are lower than in other tissues [13–
16]. High levels of Mn in the brain have been associated with
dysfunction of the basal ganglion system that can cause severe
neurological disease [13] with chronic exposure leading to a motor
syndrome resembling idiopathic Parkinson’s disease, characterised
by the presence of Alzheimer’s Type II astrocytosis [12]. We and
others have recently identified relatively high levels of a further
member of the ZnT family (SLC30;based upon homology with
other ZnT family members), ZnT10, in brain tissue [17,18]. We
have also discovered that extracellular Zn treatment down
regulates ZnT10 expression at both the mRNA and protein levels
and, using an indirect method, measured a functional response to
ZnT10 overexpression commensurate with reduced intracellular
zinc availability [17]. Interestingly recent studies have indicated
that ZnT10 may primarily transport Mn, rather than Zn. These
assumptions are based upon the fact that mutations in the ZnT10
protein impair manganese homeostasis [18] and that a Mn-
sensitive yeast strain can be rescued by expression of human
ZnT10 but not by a mutated versions, consistent with it ZnT10
acting as a manganese transporter [19,20]. Furthermore recent
studies have revealed two different homozygous frame shift
mutations in ZnT10 and have implicated these mutations with
neurological disorders, including adult onset Parkinsonism and
juvenile onset dystonia [18].
Further understanding of the ZnT family and their interactions
in the brain may elucidate a role for ZnTs and Zn and/or Mn in
the progression and pathology of AD. To date ZnT10 has not
been studied in this context. To determine if dys-regulated
expression of ZnT10 could be a factor that contributes to AD, we
investigated if there were differences in ZnT10 mRNA levels in
specimens of frontal cortex from AD patients and controls and also
if brain tissue from the APP/PS1 transgenic (Tg) mouse model
showed abnormal levels of ZnT10 mRNA expression.
Materials and Methods
Ethics statement
All human tissue was obtained from the Newcastle Brain Tissue
Resource at Newcastle University which is a Human Tissue
Authority licensed Research Tissue Bank following ethical
approval by the National Research Ethics Service. All donations
were obtained with fully informed consent following an NRES
approved protocol.
All mouse experiments were carried out in accordance with the
local animal ethics committee requirements (Howard Florey
Animal Ethics Committee) and National Health and Medical
Research Council standards of animal care (Australia).
Brain specimens
Frontal cortex RNA samples from human Alzheimer’s disease
pathology cases (n=16; female n=10, male n=6) and age-
matched controls (n=11; female n=4, male n=7; Table 1.
Individual data available in Table S1). For mouse samples, frontal
cortex brain tissue samples were obtained from 12 month old
female wild-type (WT) (n=5) and APP/PS1 mice (n=11). APP/
PS1 mice are a mouse model of AD containing two transgenes
inserted at a single locus that develop beta-amyloid deposits in the
brains by 6 to 7 months of age (http://jaxmice.jax.org/strain/
005864.html). Brain samples were removed and snap frozen
before being stored in RNA Later at 280uC.
RNA extraction and RT-qPCR
Total RNA was extracted from brain tissue using TRIzolH
reagent. Concentration of RNA was determined by measuring the
absorbance on a Nano drop ND-1000 (NanoDropH). Total RNA
preparations were analysed using an Agilent 2100 Bioanalyzer
(Agilent Technologies). Samples were stored at 280uC. RNA was
DNAse treated and synthesis of RNA into cDNA was carried out
using M-MLV RT (Promega) according to manufacturer’s
instructions in 25 mL reactions containing 0.625 mM oligo dT
primers and 1 mg RNA. Primers specific to human and mouse
ZnT10, GAPDH and 18S rRNA (reference genes) were designed
over intron/exon boundaries and are as listed in Table 2.
Topoisomerase I (TOPI) was used as a further reference gene.
TOPI primers were purchased from PrimerDesignLtd (UK).
ZnT10 was subcloned into the vector pCR2.1-TOPO TA
(Invitrogen). Standards for GAPDH and 18S rRNA products
were generated by amplifying the region between the primers
shown in Table 2, and subcloned into the vector pCR2.1-TOPO
TA (Invitrogen). A TOPI PCR product was subcloned into the
pGEM-T-easy vector to give the standard TOPI-pGEM. The
identity of the products was confirmed by sequencing (MWG
Biotech). Ten-fold serial dilutions of each of pCR2.1-hZnT10,
pCR2.1-mZnT10, pCR2.1-GAPDH, pCR2.1-18S and TOPI-
pGEM were used to generate standard curves. Primer pairs were
used at a final concentration of 250 nM and amplification was
carried out using the DNA Engine Opticon 2 (MJ Research) using
Power SYBR Green PCR Master mix (Applied Biosystems) and
thermal cycling parameters as in Table 2. Expression of the RNA
of interest was calculated by taking the Ct value, averaging the
duplicates, and then reading from the standard curve the arbitrary
concentration of the samples. Efficiency values were calculated
using the equation E= (10(21/slope) - 1)*100 and were required
to fall within the range of 80–115%. Values for ZnT10 were
expressed relative to the value for the reference gene (GAPDH and
TOPI for human samples; 18S rRNA and TOPI for mouse
samples) measured in the same cDNA sample.
Statistical Analysis
Experiments were performed in triplicate and each experiment
was repeated at least twice. Results are expressed as a ratio of
ZnT10 RNA: reference RNA, normalised to control samples.
Data were tested for normality using the Shapiro-Wilk test. For
normally distributed data differences between means were
considered significant at p,0.05 using a two tailed Student’s t
test, taking into account homogeneity of variance. Braak scores
and age were compared using non-parametric testing and the
Mann Whitney U test. Correlations were carried out using
Pearson’s correlations and, where appropriate, Spearman’s Rho
correlation. Statistical analysis was carried out using Microsoft
SPSS.
Results
To investigate if there is any association between levels of
ZnT10 expression in relevant regions of the brain and AD, we
measured ZnT10 mRNA in frontal cortex of AD patients and
controls and in frontal cortex of 12 month old female wild-type
and APP/PS1 mice.
Demographic data for the human subjects studied are shown in
Table 1. Full details for each subject can be found in Table S1.
Mean RNA Integrity numbers (RIN) were 5.32 (61.88 S.D)
with a range (from 2.5–7.3). These values indicate that, as
expected RNA degradation had occurred in some of the post
mortem brain tissue samples. For this reason all amplification
ZnT10 in Alzheimer’s Disease Brain
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products for analysis were less than 250 bp. Amplicons of this
length have been shown to be independent of RNA quality [21].
Furthermore, we found no correlation (using Spearman’s Rho
correlation) between RIN and disease progression, (indicated by
Braak score, p = 0.504). In addition, we found no significant
correlations between RIN and PMD, pH and disease state (AD vs
control) (p = 0.701, p = 0.676 and p= 0.845 respectively). Finally
there was no correlation between RIN values and ZnT10 mRNA
expression (p = 0.511).
There was no significant difference in age or post mortem delay
(PMD) between control and AD subjects. Braak staging scores
were significantly elevated (P,0.01) in AD patients (median=V)
compared with control subjects (median= II). Compared with age-
matched controls, we observed a significant decrease in ZnT10
mRNA in frontal cortex of AD patients (Figure 1). GAPDH and
TOPI showed a consistent level of expression independent of
patient diagnosis and were therefore chosen as the reference gene
and normalisation control. There was no correlation between
ZnT10 expression and Braak staging (p=0.173) in the AD tissue.
An indication that ZnT10 levels increase with age was observed,
with a trend evident for controls (p=0.088) and a near significant
correlation in AD cases (p = 0.066). When separated on the basis of
sex, brain tissue from female AD patients revealed ZnT10 mRNA
levels that correlated significantly with age (p = 0.020). Correlation
results are shown in Table 3. In the mouse samples, we observed a
significant decrease in Znt10 mRNA levels in the APP/PS1-Tg
mice compared with wild-type controls) (Figure 2). 18S rRNA and
TOPI showed a consistent level of expression independent of
mouse strain and were therefore chosen as the reference gene and
normalisation controls.
Discussion
We observed a significant decrease in ZnT10 mRNA in samples
of frontal cortex from AD patients compared with age-matched
controls, giving the first indication that ZnT10 regulation is
affected in AD. Furthermore, there was some suggestion of a sex-
specific effect; the lower levels of ZnT10 observed in female AD
cases compared with controls was statistically significant (P,0.01
by Mann-Whitney U). Despite a 45% decrease in ZnT10
expression observed in the male AD cases compared with the
controls, this did not reach statistical significance. As sample
numbers were relatively small, larger numbers are required to
draw robust conclusions from this finding. Also, there was no
significant difference in ZnT10 mRNA levels between male and
female control subjects (p=0.66) or between male and female AD
cases (p = 0.67). The observed down regulation of a transporter of
the ZnT family in AD is not without precedence. Znt3 mRNA was
found to be reduced by up to 60% in all four cortical regions tested
(medial temporal gyrus, superior occipital gyrus, superior parietal
gyrus, and superior frontal gyrus) in AD cases compared with
controls. Interestingly there was no significant differences in ZnT3
expression in the cerebellum [9].
In this study, only one area of the brain, frontal cortex, was
available to examine ZnT10 expression and whilst this region had
lower ZnT10 mRNA expression in AD patients, there are no data
as yet to indicate if this effect is region-specific. Messenger RNA
expression in brain tissue for other Zn transporters has also been
shown to be dysregulated in AD. ZIP1, ZIP6, ZnT1 and ZnT6 -
mRNAs were increased in the four cortical regions (middle
temporal gyrus, superior occipital gyrus, superior parietal gyrus,
and superior frontal gyrus), but not the cerebellum [22]. Further
research is required to establish whether ZnT10 also follows this
pattern.
Table 1. Subject demographic data.
Group Age (years, mean ± SEM) PM Delay (mean ± SEM) Braak staging (median)
Control 7168.0 (n = 11; female = 4, male = 7) 20.863.0 II
AD 7862.2 (n = 16; female = 10, male = 6) 15.461.8 V
doi:10.1371/journal.pone.0065475.t001
Table 2. Primers and cycling parameters for PCRa.
Name Primer
Product size
(bp) Cycling parametersa
bZnT10 844CGT AGC AGG TGA TTC CTT CAA C865
956CAT CTC CCA TCA CAT GCA AAA G935
140 95uC, 15 s annealing/extension 60uC, 10 s, 40 cycles
cMouse Znt10 826GTA GCA GGT GAT TCC CTG AAC846
965GTG ATG ACC ACA ACC ACG GAC945
140 95uC, 15 s annealing/extension 60uC, 10 s, 40 cycles
dGAPDH12 113TGA AGG TCG GAG TCA ACG GCT TTG136
240CAT GTA AAC CAT GTA GTT GAG GTC217
128 95uC, 15 s annealing/extension 60uC, 10 s, 40 cycles
e18S rRNA 117CAT TAA GGG CGT GGG GCG G135
247GTC GTG GGT TCT GCA TGA TG228
131 95uC, 15 s annealing/extension 56uC, 10 s, 40 cycles
aAn initial activation step of 95uC for 15 min. Times are given in the order denaturing, annealing extension, and the number of cycles is indicated.
bNumbered according to Genbank sequence NM_018713.
cNumbered according to Genbank sequence NM_001033286.
dNumbered according to Genbank sequence NM_002046.3.
eNumbered according to Genbank sequence NM_011296.
doi:10.1371/journal.pone.0065475.t002
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Figure 1. ZnT10 mRNA expression in human brain tissue. Relative levels of ZnT10 in brain tissue from AD brains (n= 16; 10 female) and
control brains (n= 11; 4 female). Data are expressed relative to GAPDH mRNA levels measured in the same samples. Negative control RT-PCR
reactions identical to those yielding the products shown except for the omission of Moloney murine leukemia virus reverse transcriptase resulted in
no products. Inset data expressed relative to TOPI mRNA levels measured in the same sample. Primers are given in Table 1. All values are shown as
mean 6 SEM ** p,0.01, * p,0.05 by Student’s t test.
doi:10.1371/journal.pone.0065475.g001
Figure 2. Znt10 mRNA expression in mouse brain tissue. Relative levels of Znt10 in brain tissue from APP/PS1 Tg mouse brains (n= 11) and
control mouse brains (n= 5). Data are expressed relative to S18 rRNA mRNA levels measured in the same samples. Negative control RT-PCR reactions
identical to those yielding the products shown except for the omission of Moloney murine leukemia virus reverse transcriptase resulted in no
products. Inset data expressed relative to TOPI mRNA levels measured in the same sample. Primers are given in Table 1. All values are shown as mean
6 SEM ** p,0.01, * p,0.05 by Student’s t test.
doi:10.1371/journal.pone.0065475.g002
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There is evidence for a significant positive correlation between
ZnT1 and Braak staging, which indicates NFT pathology. A trend
towards a positive correlation has also been shown for ZnT6 and
Braak staging [3,4]. However, in the small number of cases
analysed here there was no correlation between ZnT10 expression
and Braak staging (p=173) in the AD tissue. Intriguingly,
however, there is an indication that ZnT10 levels increase with
age, with a trend evident for controls (p=0.088) and a near
significant correlation in AD cases (p = 0.066). When separated on
the basis of sex, brain tissue from female AD patients revealed
ZnT10 mRNA levels that correlated significantly with age
(p = 0.020). Details of the implications of age-related effects on
ZnT expression have not been established, however it is known
that there is a decline in Zn status with age (reviewed by [23,24]).
Whether the decline is related to inadequate diet (such as
consumption of less red meat, rich in Zn) or a reduced ability of
the body to maintain homeostasis of this micronutrient is still
unclear.
In concordance with our findings in human subjects, we
observed lower levels of Znt10 mRNA in frontal cortex from
female APP/PS1 transgenic mice. APP/PS1 mice are a mouse
model of AD containing two transgenes inserted at a single locus.
The first is the APP sequence that is modified to encode the
human Swedish mutations K595N/M596L. Secondly, PS1
corresponds to the human presenilin 1 gene. In this case there is
a deletion of exon 9, therefore known as the DeltaE9 mutation
(http://jaxmice.jax.org/strain/005864.html). As in AD, these
mice have Ab deposits and exhibit deficits in spatial learning
[25]. The use of this mouse model to study AD is widespread, and
in particular this model has been used to identify dysregulation of
several members of the Znt family. Expression of Znt1, Znt3,
Znt4, Znt5, Znt6 and Znt7 protein in the hippocampus and
neocortex were higher in APP/PS1 mice than in controls, with
only levels for Znt5 failing to reach significance [11]. Translation
of results across species however must be applied with caution as
data using this mouse model revealed an increase in Znt3 protein
levels, whereas in human AD brain a decrease in both ZnT3
mRNA and protein levels was observed [9,10].
Other studies on the expression of Zn transporters in transgenic
mouse models of AD have investigated the distribution within
senile plaques by immunohistochemistry. Intriguingly distinct
expression patterns were uncovered, with Znt1 and Znt4 being
detected throughout the senile plaques whereas Znt3, Znt5 and
Znt6 were only associated with peripheral regions, and Znt7 was
detected predominantly in the core [11]. Our current data do not
indicate the location of Znt10 within mouse brain tissue, nor
where the differences between controls and APP/PS1 mice lie,
and further study towards obtaining higher-resolution data of this
type is warranted.
Human studies of ZnT dysregulation in AD have highlighted
the importance of specifying the stage of disease progression.
There are differences in ZnT expression profiles between AD and
the precursor states described in the literature. ZnT1 was found to
be decreased significantly in the hippocampus of subjects with the
precursor states MCI (a stage from which 95% of progress to
develop dementia) and pre-clinical AD (PCAD; where subjects
have no overt clinical manifestations of AD but pathology is
revealed post-mortem), as well as in AD [3,4]. Both ZnT4 and
ZnT6 were elevated in PCAD [4] and in the hippocampus of AD
patients [5], however there was no significant difference in levels of
either transporter between MCI and age-matched controls. The
role of ZnT10 in the progression of AD will be an important area
to address in future research, which should elucidate its level of
expression in both PCAD and MCI. Our results thus far suggest a
mechanism for ZnT10 dysregulation in the final disease state of
AD. We have previously shown that under basal conditions
ZnT10 is localised to the Golgi apparatus in a neuroblastoma cell
line model, and is translocated towards the plasma membrane on
the addition of extracellular (100 mM) Zn concurrent with a down-
regulation of ZnT10 at both the mRNA and protein levels [17].
Therefore it is possible that the increase in Zn reported in AD
brain [26] induces a down-regulation of ZnT10 mRNA, as
observed in this study. Moreover, the localisation of ZnT10
suggests two possible mechanisms through which increased
expression could exacerbate AD progression. Initially, localisation
to the Golgi apparatus may promote Ab formation by increasing
Zn sequestration in this organelle thereby enabling the binding of
Zn to APP and the inhibition of a-secretase, in a similar manner to
that hypothesised for ZnT6 [4]. Secondly, as elevated levels of Zn
induce the translocation of ZnT10 towards the plasma membrane
it may act in a similar manner as has been suggested for ZnT1 [4],
effluxing Zn into the extracellular space to providing Zn ions for
initiation of Ab deposition and senile plaque formation.
Recent observations identifying frame-shift mutations in the
SLC30A10 gene in patients with the neurological conditions
dystonia and Parkinsonism that lead to hypermanganesemia in
brain regions [18] alongside rescue experiments performed in a
yeast mutant demonstrating the ability of wild-type ZnT10 to
restore growth in a Mn sensitive yeast mutant Dpmr1 [20] indicate
that ZnT10 may act as a Mn transporter. As these experiments
have not been carried out in the presence of other metals, or by a
more direct methodology (e.g. Xenopus laevis oocyte system) the
Table 3. Correlation data examining the relationship between relative ZnT10 mRNA expression and human brain sample
parameters.
Disease Group Gender Braak Stage PMD pH Age
Control Overall 0.772 (0.123) 0.170 (20.471) 0.795 (20.122) 0.088 (0.566)
Male 0.741 (20.205) 0.504 (20.306) 0.873 (0.100) 0.148 (0.607)
Female 0.333 (20.866) 0.667 (20.500) - 0.667 (0.500)
AD Overall 0.173 (20.467) 0.123 (0.450) 0.204 (20.395) 0.066 (0.525)
Male 0.215 (20.671) 0.391 (0.500) 0.624 (0.300) 0.935 (0.51)
Female 0.425 (20.331) 0.301 (0.419) 0.023*(20.778) 0.020* (0.790)
For each correlation P values are stated with correlation coefficients in brackets. For Braak stages and when stratified for male and female data Spearman’s Rho
correlation have been carried out. For all other data Pearson’s correlations are reported. – indicates insufficient data available.
*p,0.05.
doi:10.1371/journal.pone.0065475.t003
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precise specificity of this transporter remains unknown, but the
results of the current study should nonetheless be interpreted with
cognisance of the likelihood that ZnT10 transports manganese.
Given the known link between neurological conditions and
chronic exposure to Mn, it is possibile that the dys-homeostasis
of ZnT10 observed in the AD brain is related to changes in levels
of Mn rather than Zn., Mechanisms of Mn-induced neurological
changes remain to be elucidated, although oxidative stress, protein
aggregation or altered homeostatic conditions of other divalent
metals that share similar transport mechanisms have been
suggested [13].
Overall we uncover, for the first time, changes in ZnT10
mRNA levels in a vulnerable region of AD brain, which is
paralleled in the AD transgenic mouse brain. Given the subcellular
localisation and predicted function of ZnT10 as both a Mn and Zn
transporter it is possible that tdysregulation of these metals could
contribute to increased Ab deposition and senile plaque formation
and ultimately disease progression.
Supporting Information
Table S1 Individual data for each subject including individual
actual and normalised ratios for each RT-qPCR. – indicates PCR
failed quality checks and therefore sample not used in final
analysis.
(DOCX)
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